RECORD // MECHANISM
Sermorelin Mechanism of Action: GHRH-Receptor Pharmacology
GHRH(1-29) binds a class B GPCR on pituitary somatotrophs, raises cAMP, and triggers the body's own pulsatile growth-hormone pulse — with feedback left intact.
In plain English
The sermorelin mechanism of action is upstream signaling. Sermorelin docks onto a specific receptor on the pituitary gland's GH-making cells — like a key turning one lock. That turn raises an internal messenger molecule (cAMP), which tells the cell to release a burst of growth hormone. Because sermorelin only presses the 'release' button and does not flood the body with outside hormone, the body's own brakes (somatostatin and IGF-1 feedback) still work, so GH comes out in its natural rhythm of pulses rather than a flat, constant stream.
The GHRH receptor and the cAMP/PKA cascade
Sermorelin binds the GHRH receptor (GHRH-R), a class B G-protein-coupled receptor on anterior-pituitary somatotrophs (the GH-producing cells) [1]. Receptor activation couples through Gs to adenylate cyclase, raising intracellular cyclic AMP (cAMP, a second-messenger molecule that relays the signal inside the cell) and activating protein kinase A (PKA). The downstream result is increased GH gene transcription, a trophic (growth-promoting) effect on the somatotrophs themselves, and pulsatile GH release [1].
Released GH then drives hepatic production of IGF-1 (insulin-like growth factor 1, the liver-made hormone that carries out many of GH's effects). Crucially, somatostatin (the opposing 'brake' hormone) and IGF-1 negative feedback remain intact, because sermorelin works through the body's own pituitary rather than supplying hormone from outside [1]. That preserved feedback loop is the pharmacological argument for a GHRH secretagogue over direct recombinant GH.
Sermorelin and the GH/IGF-1 somatotropic axis
Sermorelin's reach is the somatotropic axis: GHRH-R activation, pulsatile GH release, and downstream IGF-1. In healthy older men, 14 days of GHRH(1-29) at 0.5 and 1 mg twice daily produced dose-related increases in 24-hour GH and IGF-1, and at the high dose returned GH/IGF-1 parameters to a range no different from young men [5]. The axis responds; the open question this record keeps flagging is durability and long-term adult outcomes, not whether GH and IGF-1 rise.
How long does sermorelin last? Half-life and GH elevation
Sermorelin's plasma half-life is short — on the order of ~10-12 minutes after intravenous administration; GHRH(1-29) is cleared rapidly [3]. The notable pharmacokinetic feature is the disconnect between clearance and effect: a single dose elevates serum GH for roughly 3 hours despite that brief half-life [3]. The native peptide's brevity is exactly what motivated longer-acting engineered analogs, via D-Ala2 substitution and DAC (drug-affinity-complex) albumin binding. Intranasal bioavailability was only ~3-5% in the same pharmacokinetic work, which is consistent with research-community reports that oral, sublingual, and troche 'sermorelin' formats absorb poorly [3].
Sermorelin vs CJC-1295: native GHRH(1-29) vs a stabilized long-acting analog
Both sermorelin and CJC-1295 act at the GHRH receptor, but CJC-1295 is engineered for a longer half-life. The native sermorelin sequence is short-acting (the ~10-12 minute plasma half-life above) [3]. CJC-1295 incorporates a D-Ala2 substitution — which prolonged half-life and reduced metabolic clearance versus native GHRH(1-29) — and, in the DAC form, an albumin-binding maleimide that extends action to a multi-day scale. Sermorelin is the native, feedback-preserving GHRH(1-29); CJC-1295 trades some of that pulsatile fidelity for duration.
Sermorelin vs ipamorelin: GHRH analog vs ghrelin-receptor secretagogue
Sermorelin and ipamorelin are both GH secretagogues, but they act on different receptors. Sermorelin is a GHRH analog acting on the GHRH receptor [1]. Ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the ghrelin / GHS receptor — a separate receptor and pathway. The two are sometimes studied or combined for complementary GH release because they engage distinct upstream mechanisms; this record treats them as mechanistically separate molecules, not interchangeable ones.
How does sermorelin differ from direct HGH?
Sermorelin acts upstream on the pituitary to stimulate the body's own pulsatile GH, preserving somatostatin and IGF-1 feedback [1]. Injected recombinant GH supplies exogenous hormone directly and bypasses that feedback. An editorial framed the secretagogue route as a more physiologic approach to adult-onset GH insufficiency than recombinant GH [10].
How does sermorelin compare to CJC-1295?
Both act at the GHRH receptor, but CJC-1295 is engineered for a longer half-life — incorporating D-Ala2 (which prolonged half-life and reduced metabolic clearance versus native GHRH(1-29)) and, in the DAC form, an albumin-binding maleimide. Sermorelin is the native short-acting GHRH(1-29), with a ~10-12 minute plasma half-life [3].
Sermorelin vs ipamorelin: what is the difference?
Sermorelin is a GHRH analog acting on the GHRH receptor; ipamorelin is a growth-hormone-releasing peptide acting on the ghrelin / GHS receptor — a different receptor and pathway [1]. They are often studied or combined for complementary GH release, but the upstream mechanism is not the same.